Papakyriakou Athanasios, Cencetti Francesca, Puliti Elisa, Morelli Laura, Tricomi Jacopo, Bruni Paola, Compostella Federica, Richichi Barbara
Institute of Biosciences & Applications, National Centre for Scientific Research "Demokritos", GR-15341 Agia Paraskevi, Athens, Greece.
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale GB Morgagni 50, 50134 Firenze, Italy.
ACS Med Chem Lett. 2020 Mar 30;11(5):913-920. doi: 10.1021/acsmedchemlett.9b00665. eCollection 2020 May 14.
Sphingosine 1-phosphate (S1P) is a bioactive lipid mediator associated with diverse homeostatic and signaling roles. Enhanced biosynthesis of S1P, mediated by the sphingosine kinase isozymes (SK1 and SK2), is implicated in several pathophysiological conditions and diseases, including skeletal muscle fibrosis, inflammation, multiple sclerosis, and cancer. Therefore, therapeutic approaches that control S1P production have focused on the development of SK1/2 inhibitors. In this framework, we designed a series of natural monosaccharide-based compounds to enhance anchoring of the known SK1 inhibitor PF-543 at the polar head of the substrate-binding channel. Herein, we describe the structure-based design and synthesis of new glycan-containing PF-543 analogues and we demonstrate their efficiency in a TGFβ1-induced pro-fibrotic assay.
鞘氨醇-1-磷酸(S1P)是一种生物活性脂质介质,具有多种稳态和信号传导作用。由鞘氨醇激酶同工酶(SK1和SK2)介导的S1P生物合成增强,与多种病理生理状况和疾病有关,包括骨骼肌纤维化、炎症、多发性硬化症和癌症。因此,控制S1P产生的治疗方法集中在开发SK1/2抑制剂上。在此框架下,我们设计了一系列基于天然单糖的化合物,以增强已知SK1抑制剂PF-543在底物结合通道极性头部的锚定作用。在此,我们描述了新型含聚糖PF-543类似物的基于结构的设计与合成,并在TGFβ1诱导的促纤维化试验中证明了它们的有效性。